Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma

Author:

Qi Yueying1,Fan Lirong2,Ran Decong3,Xu Jieda4,Wang Yuansong5,Wu Jin5,Zhang Zhongyong5ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, 31 West Huanghe Road, Cangzhou, Hebei, China

2. Department of Endocrinology, The Traditional Chinese Medicine Hospital of Botou, West Shengli Road, Botou, Hebei, China

3. Graduate School, Hebei University of Chinese Medicine, Xingyuan Road, Shijiazhuang, Hebei, China

4. Graduate School, Chengde Medical University, Anyuan Road, Chengde, Hebei, China

5. Department of Endocrinology, Hebei Province Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, 31 West Huanghe Road, Cangzhou, Hebei, China

Abstract

Type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD) is a pathological metabolic disease characterized by high ketone lipid based on abnormal lipid metabolism. Compared with patients with single T2DM or NAFLD, T2DM complicated with NAFLD has more complicated pathogenic factors and pathological processes. Hepatocellular carcinoma (HCC), the leading malignancy arising from cirrhosis, is the second most lethal cancer globally. The purpose of this study was to clarify the main risk factors of T2DM with NAFLD and HCC. There are many challenges in the diagnosis and treatment of T2DM patients with NAFLD and HCC. The current gold standard is to adjust treatment strategy, optimize metabolic control, and improve liver phenotype. It is necessary to identify further the risk factors driving the progression of T2DM with NAFLD and HCC and evaluate new therapeutic targets, in addition to exploring the syndromic forms of T2DM combined with NAFLD and providing a theoretical basis for early prevention, diagnosis, and treatment of the disease using traditional Chinese medicine (TCM).

Funder

Research Project of Hebei Administration of Traditional Chinese Medicine

Publisher

Hindawi Limited

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3